Evidence map›Paper›PMID 35226241›Full record

ArticleJournal of neuro-oncology2022

Treatment and outcome of pediatric intracranial ependymoma after first relapse.

Zhi-Ming Liu, Zhe Han, Jun-Mei Wang, Tao Sun, Wei Liu, Bo Li, Jian Gong, Chun-de Li, Fu Zhao, Yong-Ji Tian

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Zhi-Ming LiuDepartment of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China.
Zhe HanDepartment of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China.
Jun-Mei WangDepartment of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Tao SunDepartment of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China.
Wei LiuDepartment of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China.
Bo LiDepartment of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Jian GongDepartment of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China.
Chun-de LiDepartment of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China. lichunde@bjtth.org.ORCID http://orcid.org/0000-0001-8443-8613
Fu ZhaoDepartment of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China. zhaofu@ccmu.edu.cn.ORCID http://orcid.org/0000-0002-5286-5650
Yong-Ji TianDepartment of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China. tianyongji@bjtth.org.ORCID http://orcid.org/0000-0001-9915-8630
Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAlmost 50% of children with intracranial ependymoma experience disease relapse, and their outcomes are extremely poor. The aim of this study was to investigate optimal salvage treatment for pediatric intracranial ependymoma after the first relapse and to identify prognostic factors affecting survival.

methodsWe conducted a retrospective analysis of 159 children who underwent initial treatment for intracranial ependymoma at Beijing Tiantan Hospital from 2013 to 2017.

resultsRelapse was observed in 73 patients (73/159; 45.9%), with a median age of 7.2 ± 3.5 years old. Molecular subgrouping analysis identified H3K27me3-negative PF-EPNs in 74% of patients, ST-RELA EPNs in 21% of patients, and H3K27me3-positive PF-EPNs in 5% of patients. The 5-year event-free survival (EFS) and overall survival (OS) rates after first relapse were 21.1% (95% CI 16.0-26.2) and 30.5% (95% CI 19.8-30.8), respectively. Patients with GTR at first relapse had higher 5-year EFS and 5-year OS than those with STR (P = 0.031 and P = 0.003) or no surgery (P = 0.007 and P = 0.001). Radiotherapy or re-radiotherapy at first relapse significantly prolonged 5-year EFS and OS (both P < 0.001). Patients with H3K27me3-negative PF-EPN had worse 5-year EFS and OS than those with ST-RELA EPN (P = 0.001 and P = 0.002). Multivariate analysis showed that both tumor resection and radiotherapy at first relapse had independent prognostic significance for survival (all P < 0.05).

conclusionChildren with recurrent intracranial EPN have poor outcomes, and surgery and radiotherapy at first relapse should be encouraged to improve their prognosis.

Indexed as

Brain NeoplasmsEpendymomaChildChild, PreschoolHistonesHumansNeoplasm Recurrence, LocalPrognosisProgression-Free SurvivalRetrospective StudiesTreatment OutcomeHistonesEpendymomaMolecular subgroupPediatricPrognostic factorsRadiotherapyRelapseSurgery

Identifiers

PMID35226241
OpenAlexW4214634068

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.